-
1.发明公开NUCLEAR TRANSPORT MODULATORS AND USES THEREOF 审中-公开NUKLEARTRANSPORTMODULATOREN UND ANWENDUNGEN DAVON
公开(公告)号：EP2858991A2
公开(公告)日：2015-04-15
申请号：EP13779943.3
申请日：2013-05-09
发明人： SANDANAYAKA, Vincent, P. , SHECHTER, Sharon , SHACHAM, Sharon , MCCAULEY, Dilara , BALOGLU, Erkan
IPC分类号： C07D403/12 , C07D413/12 , C07D249/08
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，包含式I化合物的药物组合物，以及使用所述化合物，盐和组合物治疗与CRM1活性相关的各种疾病的方法。
-
2.发明公开NUCLEAR TRANSPORT MODULATORS AND USES THEREOF 审中-公开NUKLEARTRANSPORTMODULATOREN UND ANWENDUNGEN DAVON
公开(公告)号：EP2736883A1
公开(公告)日：2014-06-04
申请号：EP12748083.8
申请日：2012-07-26
发明人： SANDANAYAKA, Vincent, P. , SHACHAM, Sharon , KAUFFMAN, Michael , SHECHTER, Sharon , MCCAULEY, Dilara , LANDESMAN, Yosef , SENAPEDIS, William , SAINT-MARTIN, Jean-Richard
IPC分类号： C07D213/50 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/08 , C07D403/12 , C07D413/12 , C07D487/10 , A61K31/4196 , A61K31/454 , A61K31/4439 , A61K31/421 , A61K31/506 , A61K31/497 , A61K31/407
CPC分类号： C07D487/10 , C07D213/50 , C07D401/06 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12
摘要： The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 或其药学上可接受的盐，其中变量如本文所定义和描述。 本发明还包括结构式I的化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理条件。
-
公开(公告)号：EP2665362B1
公开(公告)日：2016-03-30
申请号：EP12736172.3
申请日：2012-01-16
IPC分类号： C07D413/14 , C07D401/06 , C07D403/06 , C07D413/06 , C07D417/06 , C07D249/08 , A61K31/41 , A61P35/00
CPC分类号： C07D249/08 , C07D401/06 , C07D403/06 , C07D413/06 , C07D413/14 , C07D417/06
-
公开(公告)号：EP2665362A1
公开(公告)日：2013-11-27
申请号：EP12736172.3
申请日：2012-01-16
CPC分类号： C07D249/08 , C07D401/06 , C07D403/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The invention generally relates to the field of nuclear transport modulators,
e.g. , CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions,
e.g. , in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).-
公开(公告)号：EP2736883B1
公开(公告)日：2019-09-04
申请号：EP12748083.8
申请日：2012-07-26
发明人： SANDANAYAKA, Vincent, P. , SHACHAM, Sharon , KAUFFMAN, Michael , SHECHTER, Sharon , MCCAULEY, Dilara , LANDESMAN, Yosef , SENAPEDIS, William , SAINT-MARTIN, Jean-Richard
IPC分类号： C07D213/50 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/08 , C07D403/12 , C07D413/12 , C07D487/10 , A61K31/4196 , A61K31/454 , A61K31/4439 , A61K31/421 , A61K31/506 , A61K31/497 , A61K31/407
-
公开(公告)号：EP2736887B1
公开(公告)日：2017-10-18
申请号：EP12743846.3
申请日：2012-07-26
IPC分类号： C07D249/08 , C07D401/12 , C07D403/12 , C07D409/12 , C07D241/20 , A61K31/497 , A61K31/4439 , A61K31/506 , A61K31/498 , A61K31/55 , A61K31/5377 , A61K31/4196 , A61K31/454 , A61K31/496 , A61P35/00 , A61P31/12 , A61P29/00 , A61P27/02
CPC分类号： C07D249/08 , A61K31/4196 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D241/20 , C07D401/12 , C07D403/12 , C07D409/12
摘要： or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
-
7.发明公开HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF 有权VERWENDUNGEN DAVON的HYDRAZIDHALTIGE KERNTRANSPORTMODULATOREN
公开(公告)号：EP2736887A1
公开(公告)日：2014-06-04
申请号：EP12743846.3
申请日：2012-07-26
IPC分类号： C07D249/08 , C07D401/12 , C07D403/12 , C07D409/12 , A61K31/497 , A61K31/4439 , A61K31/506 , A61K31/498 , A61K31/55 , A61K31/5377 , A61P35/00 , A61P31/12 , A61P29/00 , A61P27/02
CPC分类号： C07D249/08 , A61K31/4196 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D241/20 , C07D401/12 , C07D403/12 , C07D409/12
摘要： or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
摘要翻译： 本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及由结构式（I）表示的化合物或其药学上可接受的盐，其中变量的值和替代值如本文所定义和描述 。 本发明还包括结构式I的化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗，调节和/或预防与CRM1活性相关的生理条件。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.025 秒)
